ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VPHM Viropharma Incorporated (MM)

49.98
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Viropharma Incorporated (MM) NASDAQ:VPHM NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 49.98 0 01:00:00

ViroPharma To Participate In The Leerink Swann Rare Disease Conference

27/09/2013 4:00pm

PR Newswire (US)


Viropharma Incorporated (MM) (NASDAQ:VPHM)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Viropharma Incorporated (MM) Charts.

EXTON, Pa., Sept. 27, 2013 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will present at the Leerink Swann Rare Disease conference at 1:40 PM ET on Wednesday October 2, 2013. The conference is being held at the Parker Meridien Hotel in New York City.

ViroPharma's presentation will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conference.

About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address diseases including hereditary angioedema (HAE), seizures in children and adolescents, adrenal insufficiency and C. difficile-associated diarrhea (CDAD). For full U.S. prescribing information on our products, please download the package inserts at http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated

Copyright 2013 PR Newswire

1 Year Viropharma Incorporated (MM) Chart

1 Year Viropharma Incorporated (MM) Chart

1 Month Viropharma Incorporated (MM) Chart

1 Month Viropharma Incorporated (MM) Chart

Your Recent History

Delayed Upgrade Clock